Market Overview:
The global intravenous antibodies market is expected to grow at a CAGR of 7.8% during the forecast period from 2018 to 2030. The increasing prevalence of autoimmune diseases, rising demand for better treatment options, and technological advancements are some of the major factors that are expected to drive the growth of this market. The global intravenous antibodies market is segmented on the basis of type into IgG, IgA, IgM, IgE, and IgD. The hospitals segment is expected to account for the largest share of this market in 2018. This segment is also projected to grow at a CAGR of 7.9% during the forecast period from 2018 to 2030.
Product Definition:
Intravenous antibodies are used to prevent or treat infections in people who have weakened immune systems.
IgG:
IgG is the first type of antibody produced by an immune system in response to an antigen. It is also known as immunoglobulin G and is a part of the larger family of antibodies.
IgA:
IgA is the largest subtype of immunoglobulin and it's primary function is to provide immunity against bacterial infections. IgA antibodies are found in highest amount in human milk, approximately 10% to 15% of total antibody production. The level of IgA antibodies in blood depends on the level of exposure to bacteria or their toxins through various routes such as respiratory route, gastrointestinal tract or by skin contact with infected individuals or animals.
Application Insights:
The hospitals segment dominated the global intravenous antibodies market in 2017. This can be attributed to factors such as presence of a large patient base and rising incidences of chronic diseases that require long-term treatment. Moreover, increasing government initiatives to control healthcare expenditure is also expected to have a positive impact on the growth rate over the forecast period.
Clinics are anticipated to emerge as the fastest-growing application segment during the forecast period owing to growing awareness about IVIG therapy among patients with rare disease disorders and their families worldwide. Increasing number of clinical trials for IVIG therapies coupled with high demand for these products from clinics across Europe and North America is further expected drive growth over next six years.
Increasing adoption of eHealth services by individuals suffering from autoimmune diseases has led them access information regarding available treatments, which has positively influenced their decision making process regarding seeking medical help at an early stage when diagnosed with an autoimmune disease or condition.
Regional Analysis:
North America dominated the global intravenous antibodies market in 2017. The presence of well-established healthcare infrastructure, high adoption of advanced technologies, and increasing prevalence of chronic diseases are some major factors responsible for its large share. In addition, rising number of product launches is also expected to drive the regional market over the forecast period.
Asia Pacific is anticipated to be one of the fastest growing regions owing to improving healthcare facilities and increasing demand for advanced therapeutics in emerging countries such as China and India.
Growth Factors:
- Increasing incidence of infectious diseases: The increasing incidence of infectious diseases is one of the key growth drivers for the intravenous antibodies market. Intravenous antibodies are used to treat a wide range of infections, including bacterial, viral, and fungal infections.
- Growing demand for targeted therapies: The growing demand for targeted therapies is another major growth driver for the intravenous antibodies market. Intravenous antibodies are increasingly being used as targeted therapies due to their ability to specifically bind to and neutralize specific targets on cancer cells or pathogens.
- Technological advancements in antibody-based therapeutics: Technological advancements in antibody-based therapeutics have led to the development of novel and more effective intravenous antibodies products that are helping to drive market growth. For instance, monoclonal antibody therapy has emerged as a promising treatment modality for various types of cancer owing to its specificity and efficacy compared with traditional chemotherapy regimens.
Scope Of The Report
Report Attributes
Report Details
Report Title
Intravenous Antibodies Market Research Report
By Type
IgG, IgA, IgM, IgE, IgD
By Application
Hospitals, Clinics, Others
By Companies
Baxter International, CSL Limited, Biotest AG, OMRIX Biopharmaceuticals, Octapharma AG, Grifols, S.A, Guizhou Taibang Biological Products, Shanghai RAAS Blood Products, Hualan Biological Engineering, Kedrion S.p.A., Beijing Tiantan Biological Products, China Biologic Products
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
165
Number of Tables & Figures
116
Customization Available
Yes, the report can be customized as per your need.
Global Intravenous Antibodies Market Report Segments:
The global Intravenous Antibodies market is segmented on the basis of:
Types
IgG, IgA, IgM, IgE, IgD
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Clinics, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Baxter International
- CSL Limited
- Biotest AG
- OMRIX Biopharmaceuticals
- Octapharma AG
- Grifols, S.A
- Guizhou Taibang Biological Products
- Shanghai RAAS Blood Products
- Hualan Biological Engineering
- Kedrion S.p.A.
- Beijing Tiantan Biological Products
- China Biologic Products
Highlights of The Intravenous Antibodies Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- IgG
- IgA
- IgM
- IgE
- IgD
- By Application:
- Hospitals
- Clinics
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Intravenous Antibodies Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Intravenous antibodies are antibodies that are injected into a person's bloodstream. They help the body fight against infection by attaching to and attacking specific cells or proteins in the body.
Some of the major players in the intravenous antibodies market are Baxter International, CSL Limited, Biotest AG, OMRIX Biopharmaceuticals, Octapharma AG, Grifols, S.A, Guizhou Taibang Biological Products, Shanghai RAAS Blood Products, Hualan Biological Engineering, Kedrion S.p.A., Beijing Tiantan Biological Products, China Biologic Products.
The intravenous antibodies market is expected to grow at a compound annual growth rate of 7.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Intravenous Antibodies Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Intravenous Antibodies Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Intravenous Antibodies Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Intravenous Antibodies Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Intravenous Antibodies Market Size & Forecast, 2018-2028
4.5.1 Intravenous Antibodies Market Size and Y-o-Y Growth
4.5.2 Intravenous Antibodies Market Absolute $ Opportunity
Chapter 5 Global Intravenous Antibodies Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Intravenous Antibodies Market Size Forecast by Type
5.2.1 IgG
5.2.2 IgA
5.2.3 IgM
5.2.4 IgE
5.2.5 IgD
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Intravenous Antibodies Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Intravenous Antibodies Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Clinics
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Intravenous Antibodies Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Intravenous Antibodies Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Intravenous Antibodies Analysis and Forecast
9.1 Introduction
9.2 North America Intravenous Antibodies Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Intravenous Antibodies Market Size Forecast by Type
9.6.1 IgG
9.6.2 IgA
9.6.3 IgM
9.6.4 IgE
9.6.5 IgD
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Intravenous Antibodies Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Clinics
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Intravenous Antibodies Analysis and Forecast
10.1 Introduction
10.2 Europe Intravenous Antibodies Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Intravenous Antibodies Market Size Forecast by Type
10.6.1 IgG
10.6.2 IgA
10.6.3 IgM
10.6.4 IgE
10.6.5 IgD
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Intravenous Antibodies Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Clinics
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Intravenous Antibodies Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Intravenous Antibodies Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Intravenous Antibodies Market Size Forecast by Type
11.6.1 IgG
11.6.2 IgA
11.6.3 IgM
11.6.4 IgE
11.6.5 IgD
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Intravenous Antibodies Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Clinics
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Intravenous Antibodies Analysis and Forecast
12.1 Introduction
12.2 Latin America Intravenous Antibodies Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Intravenous Antibodies Market Size Forecast by Type
12.6.1 IgG
12.6.2 IgA
12.6.3 IgM
12.6.4 IgE
12.6.5 IgD
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Intravenous Antibodies Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Clinics
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Intravenous Antibodies Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Intravenous Antibodies Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Intravenous Antibodies Market Size Forecast by Type
13.6.1 IgG
13.6.2 IgA
13.6.3 IgM
13.6.4 IgE
13.6.5 IgD
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Intravenous Antibodies Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Clinics
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Intravenous Antibodies Market: Competitive Dashboard
14.2 Global Intravenous Antibodies Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Baxter International
14.3.2 CSL Limited
14.3.3 Biotest AG
14.3.4 OMRIX Biopharmaceuticals
14.3.5 Octapharma AG
14.3.6 Grifols, S.A
14.3.7 Guizhou Taibang Biological Products
14.3.8 Shanghai RAAS Blood Products
14.3.9 Hualan Biological Engineering
14.3.10 Kedrion S.p.A.
14.3.11 Beijing Tiantan Biological Products
14.3.12 China Biologic Products
